SCHEMBL30781162

SCHEMBL30781162

C[C@@H](NC(=O)CCCCC(=O)O)C(=O)N[C@H](Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SLC6A5 Q9Y345 1/20 0.37
▸ FOLH1 Q04609 3/20 0.35
▸ CCKAR P32238 1/20 0.34
▸ CCKBR P32239 1/20 0.34
▸ OPRD1 P41143 1/20 0.34
▸ ITGB3 P05106 1/20 0.34
▸ ITGA2B P08514 1/20 0.34
▸ HDAC6 Q9UBN7 4/20 0.33
▸ FAAH O00519 2/20 0.33
▸ HDAC1 Q13547 2/20 0.33
▸ CASP1 P29466 1/20 0.33
▸ MMP1 P03956 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29429270 0.91 SLC6A5 (0.47) SLC6A5ITGB3ITGA2BFAAH
SCHEMBL16432430 0.91 SLC6A5 (0.47) SLC6A5ITGB3ITGA2BFAAH
SCHEMBL29429319 0.91 SLC6A5 (0.47) SLC6A5ITGB3ITGA2BFAAH
SCHEMBL16432431 0.91 SLC6A5 (0.47) SLC6A5ITGB3ITGA2BFAAH
SCHEMBL29429271 0.91 SLC6A5 (0.47) SLC6A5ITGB3ITGA2BFAAH
SCHEMBL19051472 0.87 SLC6A5 (0.39) SLC6A5ITGB3ITGA2B
SCHEMBL14167626 0.86 NOD1 (0.43) SLC6A5FOLH1
SCHEMBL28167878 0.86 BACE1 (0.39) —
SCHEMBL29630564 0.85 SLC15A2 (0.43) —
SCHEMBL29165756 0.85 CCKAR (0.36) CCKARCCKBROPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021186-A1 Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2026-01-22 — — US disclosed
EP-4565325-A2 FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-06-11 — — EP disclosed
CN-119855613-A Fatty acid-D-amino acid peptide conjugates as anaplerotic compounds for the treatment of hyperuricemia, methylmalonic urine disorder and energy metabolism disorders 匹兹堡大学高等教育联邦体系 2025-04-18 — — CN disclosed
WO-2024030367-A2 FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021186-A1 Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders HADHB, HADHA, HADH SLC6A5 744/4885FOLH1 271/4885CCKAR 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback